Chemists use electrochemistry to amp up drug manufacturing

Give your medicine a jolt. By using electrochemistry, future pharmaceuticals - including many of the top prescribed medications in the United States - soon may be easily scaled up to be manufactured in a more sustainable way. Currently, making pharmaceuticals involves creating complex organic molecules that require several chemical steps and intense energy. The process also spawns copious amounts of environmentally harmful - and usually toxic - waste.

At the heart of many popular pharmaceuticals are vicinal diamines, which contain carbon-nitrogen chemical bonds, a bioactive foundation for the medicine. According to Song Lin, assistant professor of chemistry, many widely consumed therapeutic agents have these diamines, including prescription-strength flu medicines, penicillin and some anti-cancer drugs.

Lin and his team have developed a technique that creates vicinal diamines more easily and without the toxic waste. The process uses electricity and chemistry - electrochemistry - and then employs Earth-abundant manganese.

"The current process generates a lot of waste product to make this chemical bond. When you can create a product electrosynthetically, rather than chemically, it is much more straightforward and sustainable," Lin said.

Fu N, Sauer GS, Saha A, Loo A, Lin S.
Metal-catalyzed electrochemical diazidation of alkenes.
Science. 2017 Aug 11;357(6351):575-579. doi: 10.1126/science.aan6206.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]